Evaluation of serum IGF-I, IGFBP-3 and IGF-I/IGFBP-3 molar ratio in children with growth hormone deficiency (GHD), Turner syndrome (TS) and small for gestational age (SGA) on rhGH treatment

BALLERINI, MARÍA GABRIELA; BRASLAVSKY, DÉBORA; KESELMAN, ANA; MARTINEZ, ALICIA; RODRIGUEZ, MARIA E; DOMENÉ, HORACIO; SCAGLIA, PAULA; FREIRE, ANALÍA; JASPER, HÉCTOR; BERGADÁ, IGNACIO; ROPELATO, MARÍA GABRIELA

Milan

Congreso; 9th Joint Meeting of Pediatric Endocrinology; 2013

ENDO, SLEP

Page 129 Abstr P1 d3 413 Background: Surveillance of serum IGF-I throughout rhGH treatment has become a fundamental tool to ascertain compliance and safety. However, IGF-I/IGFBP-3 molar ratio is not usually investigated. Aim: To evaluate serum IGF-I, IGFBP-3 and IGF-I/IGFBP-3 molar ratio in children on rhGH treatment. Methods: Retrospective, descriptive study of IGF-I and IGFBP-3 concentration in children throughout the first two years of rhGH treatment. IGF-I and IGFBP-3 (ICMA, Siemens) were measured in 28 GHD children (70 samples), 11 TS (27 samples), 12 SGA (31 samples). rhGH median; range dose (mg/ kg/week): GHD: 0.19; 0.14-0.24; ST and SGA: 0.30; 0.27-0.33. Results are expressed as SDS according to local data. Results: The table shows IGF-I, IGFBP-3 and IGF-I/IGFBP-3 molar ratio values. IGF-I significantly increased with treatment in GHD and TS (ANOVA: p< 0.001) and in SGA group (ANOVA: p< 0.05). Although IGFBP-3 and IGF-I/IGFBP-3 molar ratio showed an increase in all 3 groups on treatment, they did not reach statistical significance. A higher proportion of IGF-I and IGFBP-3 samples >+2SD was observed in ST and SGA versus GHD (Chi2 test: p< 0.05). Only 4 samples presented IGF-I/IGFBP3 ratio values >+2SD on rhGH (3 GHD and 1 SGA). Conclusion: GHD children on standard rhGH have IGF-I and IGFBP-3 profile within normal range, whereas a striking proportion of TS and SGA had IGF-I and IGFBP-3 higher than 2SD. Since most IGF-I/IGFBP-3 molar ratio values on these patients were within normal range, we highlight the importance of adding this index to the surveillance of rhGH treatment. Mean±SD IGF-I SDS (samples of > +2,0 SDS) IGFBP-3 SDS (samples of > +2,0 SDS) Molar Ratio SDS (samples of > +2,0 SDS) *p